Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis
| Autor: | Hong-Zhuan Chen, Zhao-hui Wei, Bai-song Wang, Hao Wang, Lu Zhang, Yan-yan Song |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Pharmacology Placebo law.invention Alkaloids Randomized controlled trial Alzheimer Disease law Internal medicine Activities of Daily Living medicine Humans Effects of sleep deprivation on cognitive performance Adverse effect Biological Psychiatry Huperzine A Randomized Controlled Trials as Topic Psychiatric Status Rating Scales business.industry Clinical trial Psychiatry and Mental health Treatment Outcome Neurology Acetylcholinesterase inhibitor Meta-analysis Regression Analysis Cholinesterase Inhibitors Neurology (clinical) business Sesquiterpenes human activities medicine.drug |
| Zdroj: | Journal of Neural Transmission. 116:457-465 |
| ISSN: | 1435-1463 0300-9564 |
| Popis: | The objective of this study was to provide an updated meta-analysis of the efficacy and safety of huperzine A (HupA) in Alzheimer's disease (AD). We searched for randomized trials comparing HupA with placebo in the treatment of AD. The primary outcome measures were mini-mental state examination (MMSE) and activities of daily living scale (ADL). Data were extracted from four randomized clinical trials and analyzed using standard meta-analysis and meta-regression methods. Oral administration of HupA for 8-24 weeks (300-500 microg daily) led to significant improvements in MMSE and ADL. The results of meta-regression showed that the estimated effect size of MMSE and ADL was increased over the treatment time. Most adverse events were cholinergic in nature and no serious adverse events occurred. Huperzine A is a well-tolerated drug that could significantly improve cognitive performance and ADL in patients with AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink